Nitric oxide-generating beta-adrenergic blocker nipradilol preserves postischemic cardiac function.

Area of Science:

• Cardiovascular Physiology
• Pharmacology
• Cardioprotection

Background:

• Preconditioning protects the heart from ischemic injury, but beta-adrenergic blockade can diminish these protective effects.
• Nitric oxide (NO) is a known preconditioning agent.
• The study investigates the potential of nipradilol, a beta-blocker with NO-generating properties, to offer simultaneous preconditioning and beta-blockade.

Purpose of the Study:

• To determine if nipradilol can precondition the heart against ischemic injury.
• To assess if nipradilol provides clinically relevant beta-blockade.
• To investigate the role of nitric oxide in nipradilol's cardioprotective effects.

Main Methods:

• Isolated rabbit hearts were subjected to 1 hour of ischemia followed by 1 hour of reperfusion.
• Experimental groups received nipradilol, L-arginine (NO donor), N(G)-nitro-L-arginine methyl ester (NO synthase inhibitor), ischemic preconditioning, esmolol (beta-blocker), or no pretreatment (control).
• Measurements included action potential duration, ventricular pressure, and infarct size.

Main Results:

• Both L-arginine and ischemic preconditioning significantly prolonged action potential duration.
• Infarct size was significantly reduced by ischemic preconditioning, L-arginine, and nipradilol compared to control.
• Only nipradilol preserved peak developed pressure during reperfusion, indicating functional protection.

Conclusions:

• Nipradilol effectively preconditions the heart against ischemic injury, likely due to its nitric oxide-producing capability.
• Nipradilol offers a dual therapeutic benefit: cardioprotection via NO generation and beta-adrenergic blockade.
• This suggests nipradilol may be a valuable agent for managing cardiac ischemia.